Skip to Main Navigation
Skip to Page Content
Share This:
https://ntp.niehs.nih.gov/go/1239

TDMS Study 05161-05 Pathology Tables

NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00
Route: GAVAGE                                                                                                     Time: 12:06:54

                                                          RATS/FINAL#1




       Facility:  Southern Research Institute

       Chemical CAS #:  23246-96-0

       Lock Date:  11/17/99

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00  
Route: GAVAGE                                                                                                     Time: 12:06:54  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0            0.01         0.033        0.1          0.33         1.0             
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50           50           50           50           50           
  Early Deaths                                                                                                                      
    Natural Death                                      6           11            6           12            2           31           
    Dosing Accident                                    2            6            3            2            3                        
    Moribund Sacrifice                                 9           11           13           14           16           19           
  Survivors                                                                                                                         
    Terminal Sacrifice                                33           22           28           22           29                        
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           50           50           50           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Colon                             (49)         (50)         (50)         (47)         (50)         (50)         
      Lipoma                                                        2 (4%)                                                          
   Intestine Large, Rectum                            (49)         (50)         (49)         (48)         (48)         (49)         
      Polyp Adenomatous                                1 (2%)                                                                       
   Intestine Large, Cecum                             (50)         (50)         (48)         (47)         (50)         (50)         
   Intestine Small, Jejunum                           (50)         (43)         (47)         (43)         (50)         (49)         
      Polyp Adenomatous                                                          1 (2%)                                             
   Liver                                              (50)         (50)         (50)         (50)         (50)         (50)         
      Cholangiocarcinoma                                                                                   1 (2%)                   
      Hemangiosarcoma                                                                                      3 (6%)      25 (50%)     
      Hemangiosarcoma, Multiple                                                                                        13 (26%)     
      Hepatocellular Carcinoma                                                                             1 (2%)       1 (2%)      
      Hepatocellular Adenoma                           1 (2%)                                                           7 (14%)     
      Hepatocellular Adenoma, Multiple                                                                     1 (2%)                   
   Mesentery                                          (10)         (10)         (18)         (14)         (13)         (5)          
      Hemangiosarcoma, Metastatic, Liver                                                                                2 (40%)     
      Sarcoma Stromal, Metastatic, Uterus                                                                  1 (8%)                   
   Oral Mucosa                                                                               (2)                                    
      Squamous Cell Carcinoma                                                                 1 (50%)                               
      Squamous Cell Papilloma                                                                 1 (50%)                               
   Pancreas                                           (50)         (50)         (50)         (46)         (50)         (50)         
      Acinus, Adenoma                                  1 (2%)                                                                       
   Stomach, Forestomach                               (50)         (50)         (50)         (49)         (49)         (50)         
   Stomach, Glandular                                 (50)         (50)         (50)         (49)         (49)         (50)         
   Tongue                                                                       (2)                                                 
      Squamous Cell Papilloma                                                    2 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00  
Route: GAVAGE                                                                                                     Time: 12:06:54  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0            0.01         0.033        0.1          0.33         1.0             
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (50)         (50)         (50)         (50)         (50)         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (50)         (50)         (50)         (50)         (50)         (50)         
      Adenoma                                          1 (2%)       1 (2%)                    1 (2%)       1 (2%)                   
      Carcinoma                                                     1 (2%)                                                          
   Adrenal Medulla                                    (50)         (49)         (50)         (50)         (50)         (50)         
      Pheochromocytoma Malignant                       1 (2%)                    1 (2%)                                             
      Pheochromocytoma Benign                          1 (2%)       5 (10%)      2 (4%)       1 (2%)       3 (6%)       1 (2%)      
   Islets, Pancreatic                                 (50)         (50)         (50)         (46)         (50)         (50)         
      Adenoma                                          2 (4%)       2 (4%)       4 (8%)                    1 (2%)                   
      Carcinoma                                                                  1 (2%)                                             
   Pituitary Gland                                    (50)         (48)         (50)         (49)         (50)         (49)         
      Pars Distalis, Adenoma                          26 (52%)     21 (44%)     21 (42%)     17 (35%)     24 (48%)      7 (14%)     
      Pars Distalis, Adenoma, Multiple                 1 (2%)       1 (2%)                                                          
      Pars Intermedia, Adenoma                                                                1 (2%)                    1 (2%)      
   Thyroid Gland                                      (49)         (50)         (49)         (49)         (50)         (50)         
      Bilateral, C-Cell, Adenoma                       1 (2%)                                                                       
      C-Cell, Adenoma                                  1 (2%)       4 (8%)       4 (8%)       6 (12%)     11 (22%)                  
      C-Cell, Carcinoma                                1 (2%)                                                                       
      Follicular Cell, Carcinoma                                    1 (2%)                                              1 (2%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Peritoneum                                                                                (1)                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (49)         (49)         (49)         (48)         (49)         (50)         
      Adenoma                                          5 (10%)      6 (12%)      8 (16%)      9 (19%)      3 (6%)       2 (4%)      
      Carcinoma                                        3 (6%)       2 (4%)       4 (8%)       3 (6%)       2 (4%)                   
      Bilateral, Adenoma                               2 (4%)       1 (2%)                    1 (2%)       1 (2%)                   
   Ovary                                              (50)         (49)         (50)         (50)         (50)         (50)         
      Granulosa Cell Tumor Malignant                                1 (2%)       1 (2%)       1 (2%)                                
      Luteoma                                          1 (2%)                                                                       
   Uterus                                             (50)         (50)         (50)         (50)         (50)         (50)         
      Carcinoma                                        1 (2%)                                                                       
      Deciduoma Benign                                                           1 (2%)                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00  
Route: GAVAGE                                                                                                     Time: 12:06:54  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0            0.01         0.033        0.1          0.33         1.0             
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - cont                                                                                                               
      Leiomyoma                                        1 (2%)                                                                       
      Leiomyosarcoma                                                1 (2%)                                                          
      Polyp Stromal                                    9 (18%)     14 (28%)     15 (30%)     11 (22%)      9 (18%)      5 (10%)     
      Polyp Stromal, Multiple                          2 (4%)                                 1 (2%)                                
      Sarcoma Stromal                                                            2 (4%)       4 (8%)       2 (4%)                   
   Vagina                                             (2)          (3)          (3)          (4)          (5)                       
      Leiomyoma                                                     1 (33%)                                                         
      Sarcoma Stromal, Metastatic, Uterus                                                     1 (25%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)         (50)         (50)         (50)         (50)         (50)         
   Lymph Node                                         (26)         (24)         (36)         (19)         (21)         (40)         
      Mediastinal, Hemangiosarcoma, Metastatic,                                                                                     
           Liver                                                                                                        2 (5%)      
   Lymph Node, Mandibular                             (50)         (49)         (48)         (50)         (50)         (50)         
   Lymph Node, Mesenteric                             (50)         (50)         (50)         (47)         (49)         (49)         
   Spleen                                             (50)         (50)         (50)         (50)         (50)         (50)         
   Thymus                                             (48)         (48)         (46)         (48)         (50)         (49)         
      Thymoma Benign                                                1 (2%)                                                          
      Thymoma Malignant                                1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (50)         (50)         (50)         (50)         (49)         (49)         
      Adenoma                                          1 (2%)       1 (2%)       1 (2%)       1 (2%)       1 (2%)                   
      Carcinoma                                        2 (4%)       3 (6%)       2 (4%)                    4 (8%)       1 (2%)      
      Fibroadenoma                                    16 (32%)     17 (34%)     22 (44%)     17 (34%)     18 (37%)      3 (6%)      
      Fibroadenoma, Multiple                          12 (24%)      4 (8%)       4 (8%)       7 (14%)      5 (10%)                  
   Skin                                               (50)         (50)         (49)         (50)         (50)         (50)         
      Basal Cell Adenoma                                            1 (2%)       1 (2%)                                             
      Basal Cell Carcinoma                             1 (2%)                    1 (2%)                                             
      Keratoacanthoma                                               1 (2%)       1 (2%)                                             
      Myxosarcoma                                      1 (2%)                                                                       
      Schwannoma Malignant                             1 (2%)                                                                       
      Squamous Cell Papilloma                                       1 (2%)                                                          
      Subcutaneous Tissue, Fibroma                     1 (2%)                    5 (10%)      3 (6%)                    1 (2%)      
      Subcutaneous Tissue, Fibrosarcoma                1 (2%)                                                                       
      Subcutaneous Tissue, Lipoma                      1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00  
Route: GAVAGE                                                                                                     Time: 12:06:54  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0            0.01         0.033        0.1          0.33         1.0             
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                                 (1)          (1)          (2)                       (6)          
      Rhabdomyosarcoma                                                           1 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (50)         (50)         (50)         (50)         (50)         (50)         
      Glioma Malignant                                                                        1 (2%)                                
      Granular Cell Tumor Malignant                                              1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (50)         (50)         (50)         (50)         (50)         
      Alveolar/Bronchiolar Adenoma                     2 (4%)                                 3 (6%)       2 (4%)                   
      Alveolar/Bronchiolar Carcinoma                                                                       1 (2%)                   
      Hemangiosarcoma                                                                                                   1 (2%)      
      Hemangiosarcoma, Metastatic, Liver                                                                   1 (2%)      17 (34%)     
      Hepatocellular Carcinoma, Metastatic,                                                                                         
          Uncertain Primary Site                                    1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Zymbal's Gland                                                  (1)                                                              
      Carcinoma                                                     1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)         (50)         (50)         (50)         (50)         (50)         
   Urinary Bladder                                    (50)         (50)         (50)         (48)         (50)         (50)         
      Papilloma                                        1 (2%)                                                                       
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)        *(50)        *(50)         
      Leukemia Mononuclear                            12 (24%)      8 (16%)     13 (26%)     18 (36%)     18 (36%)     14 (28%)     
      Lymphoma Malignant                                                                                   1 (2%)       1 (2%)      
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00  
Route: GAVAGE                                                                                                     Time: 12:06:54  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0            0.01         0.033        0.1          0.33         1.0             
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 SYSTEMIC LESIONS - cont                                                                                                            
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)        *(50)        *(50)         
      Mesothelioma Malignant                                                                  1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00  
Route: GAVAGE                                                                                                     Time: 12:06:54  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0            0.01         0.033        0.1          0.33         1.0             
                                                   MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY     MG/KG/DY        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            47          47          48          47          50          50               
     Total Primary Neoplasms                          115         102         119         109         113          84               
                                                                                                                                    
   Total Animals with Benign Neoplasms                 45          42          45          41          45          22               
     Total Benign Neoplasms                            90          84          92          80          80          27               
                                                                                                                                    
   Total Animals with Malignant Neoplasms              20          16          21          28          28          47               
     Total Malignant Neoplasms                         25          18          27          29          33          57               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                          1                       2           2          17               
     Total Metastatic Neoplasm                                      1                       3           2          21               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                           1                                                               
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00  
Route: GAVAGE                                                                                                     Time: 12:06:54  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS MALE                     0            1.0                                                                 
                                                   MG/KG/DY     MG/KG/DY                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50                                                               
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 1            9                                                               
    Natural Death                                                  36                                                               
    Dosing Accident                                                 2                                                               
  Survivors                                                                                                                         
    Terminal Sacrifice                                49            3                                                               
                                                                                                                                    
  Animals Examined Microscopically                    50           50                                                               
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (50)         (50)                                                             
      Hemangiosarcoma                                              19 (38%)                                                         
      Hemangiosarcoma, Multiple                                    24 (48%)                                                         
      Hepatocellular Adenoma                                        3 (6%)                                                          
      Hepatocellular Adenoma, Multiple                              1 (2%)                                                          
      Hepatocholangiocarcinoma                                      1 (2%)                                                          
   Mesentery                                          (8)          (9)                                                              
      Chordoma, Metastatic, Mesentery                               1 (11%)                                                         
      Hemangiosarcoma, Metastatic, Liver                            4 (44%)                                                         
   Pancreas                                           (50)         (50)                                                             
      Hemangiosarcoma, Metastatic, Liver                            2 (4%)                                                          
      Acinus, Adenoma                                  1 (2%)       1 (2%)                                                          
   Salivary Glands                                    (50)         (50)                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (50)                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (49)         (50)                                                             
   Adrenal Medulla                                    (49)         (50)                                                             
      Pheochromocytoma Benign                          2 (4%)       2 (4%)                                                          
   Pituitary Gland                                    (50)         (49)                                                             
      Pars Distalis, Adenoma                          11 (22%)      2 (4%)                                                          
      Pars Distalis, Carcinoma                         1 (2%)                                                                       
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00  
Route: GAVAGE                                                                                                     Time: 12:06:54  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS MALE                     0            1.0                                                                 
                                                   MG/KG/DY     MG/KG/DY                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - cont                                                                                                             
   Thyroid Gland                                      (50)         (50)                                                             
      C-Cell, Adenoma                                  3 (6%)       3 (6%)                                                          
      C-Cell, Carcinoma                                1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Peritoneum                                         (4)          (3)                                                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Epididymis                                         (50)         (50)                                                             
   Preputial Gland                                    (50)         (50)                                                             
      Adenoma                                          2 (4%)                                                                       
      Carcinoma                                                     1 (2%)                                                          
   Seminal Vesicle                                    (50)         (50)                                                             
   Testes                                             (50)         (50)                                                             
      Bilateral, Interstitial Cell, Adenoma           18 (36%)                                                                      
      Interstitial Cell, Adenoma                      21 (42%)      7 (14%)                                                         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)         (49)                                                             
   Lymph Node                                         (13)         (39)                                                             
      Mediastinal, Hemangiosarcoma, Metastatic,                                                                                     
           Liver                                                    3 (8%)                                                          
   Lymph Node, Mandibular                             (50)         (50)                                                             
   Lymph Node, Mesenteric                             (50)         (50)                                                             
   Spleen                                             (50)         (49)                                                             
      Hemangiosarcoma, Metastatic, Liver                            1 (2%)                                                          
   Thymus                                             (49)         (49)                                                             
      Thymoma Benign                                   1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (50)         (50)                                                             
      Keratoacanthoma                                  2 (4%)       1 (2%)                                                          
      Squamous Cell Papilloma                          1 (2%)                                                                       
      Subcutaneous Tissue, Fibroma                     2 (4%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00  
Route: GAVAGE                                                                                                     Time: 12:06:54  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS MALE                     0            1.0                                                                 
                                                   MG/KG/DY     MG/KG/DY                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)         (50)                                                             
      Osteosarcoma                                                  1 (2%)                                                          
   Skeletal Muscle                                    (1)          (5)                                                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (50)         (50)                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (50)                                                             
      Alveolar/Bronchiolar Adenoma                                  3 (6%)                                                          
      Alveolar/Bronchiolar Carcinoma                   1 (2%)                                                                       
      Chordoma, Metastatic, Mesentery                               1 (2%)                                                          
      Hemangiosarcoma, Metastatic, Liver                           26 (52%)                                                         
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Ear                                                (1)          (1)                                                              
      Neural Crest Tumor                                            1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)         (50)                                                             
   Urinary Bladder                                    (50)         (50)                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)                                                             
      Leukemia Mononuclear                             2 (4%)       9 (18%)                                                         
      Lymphoma Malignant                                            2 (4%)                                                          
      Mesothelioma Malignant                           4 (8%)       3 (6%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 05161-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                            RIDDELLIINE                                        Date: 12/15/00  
Route: GAVAGE                                                                                                     Time: 12:06:54  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS MALE                     0            1.0                                                                 
                                                   MG/KG/DY     MG/KG/DY                                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            47          49                                                               
     Total Primary Neoplasms                           73          85                                                               
                                                                                                                                    
   Total Animals with Benign Neoplasms                 47          15                                                               
     Total Benign Neoplasms                            64          23                                                               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               9          47                                                               
     Total Malignant Neoplasms                          9          60                                                               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              1          30                                                               
     Total Metastatic Neoplasm                          4          39                                                               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                              1                                                               
     Total Uncertain Neoplasms                                      2                                                               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------